NeoCura Ag
TM
NeoCura Ag is a frontier treatment regimen based on the artificial intelligence (AI) technology. Through high-throughput sample sequencing and AI algorithm prediction, it identifies the optimal neoantigen fragments that can be efficiently bound to and presented by patients' tumor cells, so as to trigger the immune response of the body to tumor-specific mutants, then synthesizes the corresponding coding mRNA neoantigen preparations for tumor treatment. Compared to traditional drugs, NeoCura Ag features stronger immunogenicity that can induce specific anti-tumor immune response in humans.Based on its R&D experience and technical superiority, NeoCura develops personalized neoantigens for different individuals and establishes public neoantigen libraries for multiple types of cancers through sequencing and data analysis of large number of clinical samples collected from tumor patients, which significantly reduces the cost of neoantigen drug therapy and shortens the preparation time. So far, NeoCura has cooperated with many hospitals to conduct relevant trials.
TM
TM
Product Highlights
Less toxicities
Avoid immune tolerance
retaining long-acting immunological memory
Better efficacy in combination therapy
Technical Superiority
Compared with other public algorithms, the NeoCura cancer neoantigen prediction platform ALPINE, independently developed with sole ownership, offers 30% or higher accuracy of prediction compared to the public dataset of the Tumor Neoantigen Selection Alliance (TESLA);
Based on deep learning, the self-built MATHLA model is significantly superior to the models universally used in the industry in terms of the prediction accuracy and coverage of HLA allele-binding peptide mapping;
NeoCura has accumulated vast amounts of tumor patient neoantigen sequencing and validation data (completed neoantigen-related sequencing data of 7 types of tumors in hundreds of patients and over 2000 chains of peptide immunogenicity data);
TM
Based on self-owned large-scale experimental validation data, the mRNA sequence optimization and computation model enhances mRNA sequence translation efficiency by 5-10 times;
The CMC process for RNA drugs has been established at domestic leading quality.
Clinical Value
Short-term value
For early patients, NeoCura Ag can be used in combination with other therapies to achieve better efficacy and improve long-term prognosis. It is expected to be the last treatment option for advanced patients who have failed multiple lines of therapies;
TM
Interim value
NeoCuraAg can be used in combination with surgery or other tumor therapies to eliminate residual tumor lesions, reduce risk of relapse and metastasis, prolong survival, improve prognosis and quality of life;
